Lymphoma Clinical Trials in Beijing, Beijing Municipality
111 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 111 trials
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled198 locationsNCT06136559
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled173 locationsNCT06943872
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled76 locationsNCT05283720
Recruiting
Phase 2
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals155 enrolled17 locationsNCT06539182
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 1Phase 2
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
T-cell LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPTCL
Peking University People's Hospital30 enrolled1 locationNCT06874946
Recruiting
Phase 1Phase 2
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital50 enrolled1 locationNCT06880913
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 2
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
B-cell Lymphoma Refractory
Daihong Liu10 enrolled1 locationNCT07321301
Recruiting
Phase 2
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.66 enrolled15 locationsNCT07154264
Recruiting
Phase 2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1Phase 2
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ascentage Pharma Group Inc.123 enrolled18 locationsNCT04494503
Recruiting
Phase 1Phase 2
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences20 enrolled1 locationNCT06834529
Recruiting
Phase 1
Phase Ib Clinical Study of Keynatinib
Lymphoma, B-Cell
Medolution Ltd.75 enrolled4 locationsNCT04807881
Recruiting
Phase 1Phase 2
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
T-lymphoblastic LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Beijing Tongren Hospital43 enrolled1 locationNCT06376721
Recruiting
Phase 2
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Beijing Tongren Hospital100 enrolled1 locationNCT06081478
Recruiting
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Carcinoma, Non-Small Cell LungAnaplastic Lymphoma Kinase I1171NEnsartinib
Peking Union Medical College Hospital490 enrolled1 locationNCT05498064